CN108159258A - Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof - Google Patents
Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof Download PDFInfo
- Publication number
- CN108159258A CN108159258A CN201810163406.XA CN201810163406A CN108159258A CN 108159258 A CN108159258 A CN 108159258A CN 201810163406 A CN201810163406 A CN 201810163406A CN 108159258 A CN108159258 A CN 108159258A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicinal material
- lumbar vertebra
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 208000029761 vertebral disease Diseases 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241000522254 Cassia Species 0.000 claims abstract description 9
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 9
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 9
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 9
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 9
- 241000195947 Lycopodium Species 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 9
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 9
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 9
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 9
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 9
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 124
- 235000019441 ethanol Nutrition 0.000 claims description 61
- 239000000463 material Substances 0.000 claims description 44
- 239000000243 solution Substances 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 238000007654 immersion Methods 0.000 claims description 12
- 239000013558 reference substance Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 10
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 10
- 238000009736 wetting Methods 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000012085 test solution Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000005325 percolation Methods 0.000 claims description 5
- 235000019640 taste Nutrition 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 3
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 238000004176 ammonification Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- -1 filtering Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 229920000896 Ethulose Polymers 0.000 claims description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000010408 potassium alginate Nutrition 0.000 claims description 2
- 239000000737 potassium alginate Substances 0.000 claims description 2
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 229940127003 anti-diabetic drug Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- RWXIFXNRCLMQCD-CZIWJLDFSA-N (20R)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-CZIWJLDFSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 235000014490 good eating habits Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004140 ketosis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind for the treatment of with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof, which is made of the raw material of following weight parts:10~20 parts of 120~130 parts of lycopodium calvatum, 110~125 parts of rhizoma atractylodis, 100~110 parts of Radix Glycyrrhizae, 80~95 parts of Radix Ophiopogonis, 75~90 parts of Schisandra chinensis, 60~75 parts of Rhizoma Chuanxiong, 40~55 parts of pueraria lobata, 40~50 parts of Radix Paeoniae Alba, 35~45 parts of Poria cocos, 30~40 parts of rhizoma alismatis, 20~30 parts of Chinese cassia tree, 10~20 parts of Chinese yam and ginsenoside.The Chinese medicine composition of the present invention can effectively control blood glucose, treat the diabetes with lumbar vertebra disease intercurrent disease, patient is made to get well, with obvious effects, treatment cycle is short and recurrence rate is low, will not generate the dependence to drug.
Description
Technical field
The invention belongs to diabetes medicament fields, and in particular to a kind of Chinese medicine for treating diabetes composition treated with lumbar vertebra disease
And preparation method thereof.
Background technology
Diabetes be a kind of complex disease because syndrome, be the hormone due to internal insulin deficit or antagonism insulin
Increase or cannot bring into normal play in target cell glucose caused by physiological action, protein and lipid-metabolism of insulin is disorderly
A kind of random syndrome.It is characterized in that occur when concentration of glucose raising and glucose in urine, blood glucose extremely are excessively high in blood circulation typical
" three-many-one-little " symptom, i.e., more drinks, diuresis are eaten and weight loss, and with fatigue and weak more.Ketosis acid can occur for severe patient
Poisoning, hypertonicity diabetic coma, and easily merge multi-infection.With the extension of the course of disease, metabolic disorder can cause eye, kidney,
The chronic disease of the histoorgans such as nerve, blood vessel and heart.If heart disease, brain occur for treatment that cannot be timely, appropriate
Vascular lesion, renal failure, lose the sight of both eyes, lower limbs necrosis situations such as, become the main reason for disabling, is lethal.And diabetes
Incidence is high, and either developed country or developing country, the incidence of diabetes are all rising year by year.
Some patientss take drug or the insulin injection of a large amount of hypoglycemic to treat diabetes, the state of an illness as a result occur
Tolerance, the antidiabetic drug for only taking a large amount of dosage can just have hypoglycemic effect, and can also be generated to medicine using insulin
The dependence of object, causes blood glucose to be difficult to control.The main reason for such case is caused to occur, is is that people " control diabetes in time
Treat " misunderstanding, the traditional Chinese medical science is more correct to the cause of disease view of diabetes, it is believed that mainly overfeeding delicious food, five excessive emotional activities, sexual overstrain,
The insufficient several factors of the pyreticosis dry and native endowment of fire.In fact for the treatment of diabetes, patient answers reasonable meals in daily life
Food, controls and forms good eating habit, is then treated by appropriate Chinese medicine, could effectively control blood glucose, stablizes disease
Feelings are got well.However diabetes, also often with hyperglycemia, the intercurrent diseases such as hyperlipidemia and lumbar vertebra disease, this is controlled to Chinese medicine
Treating increases its difficulty, therefore researches and develops to have to treat and be had a very important significance with the Chinese medicine for treating diabetes of lumbar vertebra disease.
Invention content
The object of the present invention is to provide a kind of effective treatment with the Chinese medicine for treating diabetes composition of lumbar vertebra disease.
In order to achieve the above objectives, Chinese medicine composition of the present invention is made of the raw material of following weight parts:Lycopodium calvatum 120~
130 parts, 110~125 parts of rhizoma atractylodis, 100~110 parts of Radix Glycyrrhizae, 80~95 parts of Radix Ophiopogonis, 75~90 parts of Schisandra chinensis, 60~75 parts of Rhizoma Chuanxiong,
40~55 parts of pueraria lobata, 40~50 parts of Radix Paeoniae Alba, 35~45 parts of Poria cocos, 30~40 parts of rhizoma alismatis, 20~30 parts of Chinese cassia tree, 10~20 parts of Chinese yam
With 10~20 parts of ginsenoside.
In the present invention, the extracting mode step of the Rhizoma Chuanxiong active ingredient is as follows:
A) Rhizoma Chuanxiong is taken to shred, 60% ethanol wet 8~15 minutes;
B) 65% ethyl alcohol is added in into the medicinal material after wetting to impregnate 6~10 hours;
C) medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~
The speed of 180ml/min/kg medicinal materials carries out diacolation;
D) percolate is collected, removal solvent is up to Rhizoma Chuanxiong extract.
In the present invention, the extracting mode step of the effective component of paeonia lactiflora is as follows:
A) Radix Paeoniae Alba is taken to shred, 55% ethanol wet 10~15 minutes;
B) 70% ethyl alcohol is added in into the medicinal material after wetting to impregnate 10~15 hours;
C) medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~
The speed of 180ml/min/kg medicinal materials carries out diacolation;
D) percolate is collected, removal solvent is up to radix paeoniae alba extraction.
In the present invention, 50~60% ethanol percolations of the Schisandra chinensis collect percolate, recycle ethyl alcohol, are concentrated into thick paste.
Preferably, Chinese medicine composition of the present invention is made of the raw material of following weight parts:125 parts of lycopodium calvatum, rhizoma atractylodis 115
Part, 105 parts of Radix Glycyrrhizae, 90 parts of Radix Ophiopogonis, 80 parts of Schisandra chinensis, 70 parts of Rhizoma Chuanxiong, 45 parts of pueraria lobata, 45 parts of Radix Paeoniae Alba, 40 parts of Poria cocos, rhizoma alismatis 35
15 parts of part, 25 parts of Chinese cassia tree, 15 parts of Chinese yam and ginsenoside.
Another object of the present invention provides the preparation method of the Chinese medicine composition, which is:
(1) medicinal material of parts by weight is spare needed for weighing;
(2) Rhizoma Chuanxiong is taken to shred, 60% ethanol wet 8~15 minutes adds in 65% ethyl alcohol into the medicinal material after wetting and impregnates 6
~10 hours, the medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~
The speed of 180ml/min/kg medicinal materials carries out diacolation, collects percolate, removal solvent is up to Rhizoma Chuanxiong extract;
(3) Radix Paeoniae Alba is taken to shred, 55% ethanol wet 10~15 minutes adds in the immersion of 70% ethyl alcohol into the medicinal material after wetting
10~15 hours, the medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~
The speed of 180ml/min/kg medicinal materials carries out diacolation, collects percolate, removal solvent is up to radix paeoniae alba extraction;
(4) 35~45 degrees Celsius of flooding 2 times of Radix Ophiopogonis, 1~1.5 hour every time, merges leaching liquor, filtration, filtrate
It is concentrated into the thick paste that relative density is 1.2~1.3;
(5) 50~60% ethanol percolations of Schisandra chinensis collect percolate, recycle ethyl alcohol, are concentrated into thick paste;
(6) after Chinese cassia tree is crushed, with the extraction of 70%~85% ethanol solution twice, merge extracting solution, extracting solution is concentrated
To no alcohol taste, the water of doubling dose is added to dilute and is stirred evenly, stands and removes sediment, obtain cinnamomum cassia extract;
(7) lycopodium calvatum, rhizoma atractylodis, Radix Glycyrrhizae, pueraria lobata, Poria cocos, rhizoma alismatis water decoct 3~4 times, 2.5~3.5 hours every time, close
And decoction liquor, filtering, filtrate are concentrated into the thick paste that relative density is 1.15~1.25, cooling, adding in ethyl alcohol makes the alcohol content be
40%~60%, stand, take supernatant, recycle ethyl alcohol, concentration and gained thick paste in Chinese yam fine powder, ginsenoside, (2)-(6) and
Extract merges, and dry, adding pharmaceutic adjuvant, routinely dosage form needed for clinic is made in preparation process.
Chinese medicine composition of the present invention, can be prepared by conventional preparation process becomes clinically-acceptable various dosage forms
Such as:Granule, tablet, pill, capsule, injection or oral liquid, tincture, suppository, mixture, powder, lotion, film, dripping pill
Deng.
In the present invention, ethylhydroxyethylcellulose, chitin, methyl can also be added in preparation made from Chinese medicine composition
Cellulose, sodium alginate, potassium alginate, calcium alginate, hydroxyethyl cellulose, hydroxypropyl cellulose, dextrin etc..
Preferably, the dosage form of Chinese medicine composition of the present invention is granule, every gram of the granule containing ginsenoside Re 3~
6mg。
In the present invention, the assay method of the ginsenoside Re can be:
The preparation of reference substance solution:It is appropriate that precision weighs ginsenoside Re's reference substance, and methanol is added to be respectively prepared in every 1ml and is contained
The solution of ginsenoside Re 0.4mg, as reference substance solution;
The preparation of test solution:This product is taken, is ground well, precision weighs 1 gram, and add methylene chloride 15ml, and water-bath reflux 0.5 is small
When, filtration discards dichloromethane, and residue volatilizes adds the water 2ml of n-butanol saturation soak after solvent together with filter paper, and precision adds in use
Water-saturated n-butanol 40ml ultrasonic extraction 30min, precision measure supernatant, and twice times of amount of ammonification test solution shakes up, take upper strata molten
Liquid is evaporated, and residue adds ethyl alcohol to dissolve, and quantitatively moves in 2ml measuring bottles, ethyl alcohol is added to be diluted to scale, shake up to get;
Chromatographic condition:It is filler with octadecylsilane chemically bonded silica;
- 0.05% phosphoric acid solution of acetonitrile that volume ratio is 50: 80 is mobile phase;Detection wavelength 203nm;Measuring method:Respectively
Precision draws reference substance solution and each 10 μ l of test solution, injects hplc determination.
The Chinese medicine composition of the present invention can effectively control blood glucose, treat the diabetes with lumbar vertebra disease intercurrent disease, make disease
People gets well, with obvious effects, and treatment cycle is short and recurrence rate is low, will not generate the dependence to drug, blood glucose is caused to be difficult to
Control.
Specific embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.As long as in addition, technical characteristic involved in the various embodiments of the present invention described below each other it
Between do not form conflict and can be combined with each other.
Embodiment 1:
The present embodiment Chinese medicine composition is made of the raw material of following weight parts:It is 125 parts of lycopodium calvatum, 115 parts of rhizoma atractylodis, sweet
105 parts of grass, 90 parts of Radix Ophiopogonis, 80 parts of Schisandra chinensis, 70 parts of Rhizoma Chuanxiong, 45 parts of pueraria lobata, 45 parts of Radix Paeoniae Alba, 40 parts of Poria cocos, 35 parts of rhizoma alismatis, Chinese cassia tree
15 parts of 25 parts, 15 parts of Chinese yam and ginsenoside.
The Chinese medicine composition of the present embodiment is prepared by following preparation methods:
(1) medicinal material of parts by weight is spare needed for weighing;
(2) Rhizoma Chuanxiong is taken to shred, 60% ethanol wet 8~15 minutes adds in 65% ethyl alcohol into the medicinal material after wetting and impregnates 6
~10 hours, the medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~
The speed of 180ml/min/kg medicinal materials carries out diacolation, collects percolate, removal solvent is up to Rhizoma Chuanxiong extract;
(3) Radix Paeoniae Alba is taken to shred, 55% ethanol wet 10~15 minutes adds in the immersion of 70% ethyl alcohol into the medicinal material after wetting
10~15 hours, the medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~
The speed of 180ml/min/kg medicinal materials carries out diacolation, collects percolate, removal solvent is up to radix paeoniae alba extraction;
(4) 35~45 degrees Celsius of flooding 2 times of Radix Ophiopogonis, 1~1.5 hour every time, merges leaching liquor, filtration, filtrate
It is concentrated into the thick paste that relative density is 1.2~1.3;
(5) 50~60% ethanol percolations of Schisandra chinensis collect percolate, recycle ethyl alcohol, are concentrated into thick paste;
(6) after Chinese cassia tree is crushed, with the extraction of 70%~85% ethanol solution twice, merge extracting solution, extracting solution is concentrated
To no alcohol taste, the water of doubling dose is added to dilute and is stirred evenly, stands and removes sediment, obtain cinnamomum cassia extract;
(7) lycopodium calvatum, rhizoma atractylodis, Radix Glycyrrhizae, pueraria lobata, Poria cocos, rhizoma alismatis water decoct 3~4 times, 2.5~3.5 hours every time, close
And decoction liquor, filtering, filtrate are concentrated into the thick paste that relative density is 1.15~1.25, cooling, adding in ethyl alcohol makes the alcohol content be
40%~60%, stand, take supernatant, recycle ethyl alcohol, concentration and gained thick paste in Chinese yam fine powder, ginsenoside, (2)-(6) and
Extract merges, dry, and adding pharmaceutic adjuvant, routinely granule is made in preparation process, and every gram of particle contains ginsenoside Re
4.5mg。
Wherein, the assay method of the ginsenoside Re is:
The preparation of reference substance solution:It is appropriate that precision weighs ginsenoside Re's reference substance, and methanol is added to be respectively prepared in every 1ml and is contained
The solution of ginsenoside Re 0.4mg, as reference substance solution;
The preparation of test solution:This product is taken, is ground well, precision weighs 1 gram, and add methylene chloride 15ml, and water-bath reflux 0.5 is small
When, filtration discards dichloromethane, and residue volatilizes adds the water 2ml of n-butanol saturation soak after solvent together with filter paper, and precision adds in use
Water-saturated n-butanol 40ml ultrasonic extraction 30min, precision measure supernatant, and twice times of amount of ammonification test solution shakes up, take upper strata molten
Liquid is evaporated, and residue adds ethyl alcohol to dissolve, and quantitatively moves in 2ml measuring bottles, ethyl alcohol is added to be diluted to scale, shake up to get;
Chromatographic condition:It is filler with octadecylsilane chemically bonded silica;
- 0.05% phosphoric acid solution of acetonitrile that volume ratio is 50: 80 is mobile phase;Detection wavelength 203nm;Measuring method:Respectively
Precision draws reference substance solution and each 10 μ l of test solution, injects hplc determination.
Embodiment 2:
The present invention is to causing the influence of adult rat adrenal tissue element hyperglycemia model.
Type-2 diabetes mellitus is common complaint among the elderly, frequently-occurring disease.Through clinical efficacy and it is experimentally confirmed that Chinese traditional medicine composition of the present invention
Object has hypoglycemic effect.This experiment is usually to accelerate glycogen and lipolysis in rat body with adrenal gland, makes Portugal in rat serum
Grape sugar concentration increases, and adrenaline can also inhibit the insulin releasing in rat body.Simultaneously doses grape is filled to rat again
Sugar accelerates to cause hyperglycemia model.
Material is as follows:
Animal:Wistar rats, half male and half female, weight are 220 ± 25g
Drug:1. original powder of the present invention, effective dose is respectively 20 times of clinical application amount.
2. GUBEN JIANGTANG JIAONANG.
Method and result:
Rat 30 is taken, is randomly divided into 3 groups, every group 10.First group is negative control group, gives distilled water.Second group
For positive controls, to GUBEN JIANGTANG JIAONANG, third group gives the Chinese medicine of the present invention, and gastric infusion, medicine journey one month, last is given
1 hour after medicine, by the dosage Injection of Adrenaline of 500 μ g/kg, cause adrenal gland hyperglycemia model, at the same with glucose 1g/kg
Dosage gavage, establish to acceleration model, measure empty stomach, half an hour, 1 hour, 2 hours, 3 respectively using glucose oxidase method
The change of blood sugar of hour, the result is shown in tables 1.
Influence of 1 Chinese medicine of the present invention of table to adrenaline moulding rat blood sugar content
As a result it and discusses:
Animal hyperglycemia model caused by adrenaline is a kind of method increased with simulation irritability blood glucose, is equivalent to adult
Morbidity state after the Psychomotor test Battrey sexual stimulus of type 2 diabetes patient, therefore with certain clinical meaning.And consolidate hypoglycemic
It has been that past research institute confirms, therefore be selected to this experiment as Chinese medicine that capsule, which can be substantially reduced adrenal gland disposition hyperglycemia,
Positive control.Originally the experimental results showed that, the present invention can preferably inhibit the rat blood sugar caused by adrenaline to increase reaction,
There is apparent hypoglycemic effect, can be used for treating diabetes.
Specific case 1:
There is polydipsia in patient Mr. Zhang 47 years old before 3 years, fatigue and weak, frequent micturition urine is more, and body is gradually thin, fasting blood-glucose
10.5mmol/l, and with the symptom of lumbar vertebra disease, per hypoglycemic agent is taken before the meal, through multiple hospitals, a variety of method treatments are imitated
Fruit unobvious.Chinese medicine of the present invention is taken after 1 month, diversion is reduced, and urine is reduced, and fasting blood-glucose is maintained at 6mmol/l or so.
Specific case 2:
48 Mr. Sun due to fighting for a long time in market, has formed very bad eating habit and has been accustomed to work and rest, with sugar
Urine disease, blood glucose is unstable always, and with the symptom of lumbar vertebra disease, in order to solve this problem, grandson first ate it raw antidiabetic drug, beat
Insulin is crossed, but blood glucose still can drop, however Mr.'s Sun rational diet and work and rest, taking prescription the latter of the present invention
Month, the state of an illness is clearly better.
Specific case 3:
57 Miss Wu, with diabetes for many years, blood glucose is unstable always, and with the symptom of lumbar vertebra disease, is
Solve the problems, such as this, Miss Wu ate antidiabetic drug, beat insulin, but blood glucose still can drop, however Miss Wu closes
Diet and work and rest are managed, after persistently having taken Chinese medicine of the present invention, the state of an illness has obtained no small change, per blood glucose will after a period of time
There is steady and regular decline, persistently take two after half a month, glucostasis, fasting blood-glucose is maintained at 5.7mmol/l or so.
As it will be easily appreciated by one skilled in the art that the foregoing is merely illustrative of the preferred embodiments of the present invention, not to
The limitation present invention, all any modification, equivalent and improvement made all within the spirits and principles of the present invention etc., should all include
Within protection scope of the present invention.
Claims (10)
1. a kind of Chinese medicine for treating diabetes composition treated with lumbar vertebra disease, which is characterized in that the Chinese medicine composition includes following heavy
Measure the component of number:120~130 parts of lycopodium calvatum, 110~125 parts of rhizoma atractylodis, 100~110 parts of Radix Glycyrrhizae, 80~95 parts of Radix Ophiopogonis, the five tastes
Son 75~90 parts, 60~75 parts of Rhizoma Chuanxiong, 40~55 parts of pueraria lobata, 40~50 parts of Radix Paeoniae Alba, 35~45 parts of Poria cocos, 30~40 parts of rhizoma alismatis,
10~20 parts of 20~30 parts of Chinese cassia tree, 10~20 parts of Chinese yam and ginsenoside.
2. treatment according to claim 1 is with the Chinese medicine for treating diabetes composition of lumbar vertebra disease, which is characterized in that the Rhizoma Chuanxiong
The extracting mode step of active ingredient is as follows:
A) Rhizoma Chuanxiong is taken to shred, with 60% ethanol wet 8~15 minutes;
B) 65% ethyl alcohol is added in into the medicinal material after wetting to impregnate 6~10 hours;
C) medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~180ml/
The speed of min/kg medicinal materials carries out diacolation;
D) percolate is collected, removal solvent is up to Rhizoma Chuanxiong extract.
3. treatment according to claim 1 is with the Chinese medicine for treating diabetes composition of lumbar vertebra disease, which is characterized in that the Radix Paeoniae Alba
The extracting mode step of active ingredient is as follows:
A) Radix Paeoniae Alba is taken to shred, 55% ethanol wet 10~15 minutes;
B) 70% ethyl alcohol is added in into the medicinal material after wetting to impregnate 10~15 hours;
C) medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~180ml/
The speed of min/kg medicinal materials carries out diacolation;
D) percolate is collected, removal solvent is up to radix paeoniae alba extraction.
4. treatment according to claim 1 is with the Chinese medicine for treating diabetes composition of lumbar vertebra disease, which is characterized in that the five tastes
Sub 50~60% ethanol percolations, collect percolate, recycle ethyl alcohol, are concentrated into thick paste.
5. treatment according to claim 1 is with the Chinese medicine for treating diabetes composition of lumbar vertebra disease, which is characterized in that the Chinese medicine group
Close the component that object includes following portions by weight:125 parts of lycopodium calvatum, 115 parts of rhizoma atractylodis, 105 parts of Radix Glycyrrhizae, 90 parts of Radix Ophiopogonis, Schisandra chinensis 80
Part, 70 parts of Rhizoma Chuanxiong, 45 parts of pueraria lobata, 45 parts of Radix Paeoniae Alba, 40 parts of Poria cocos, 35 parts of rhizoma alismatis, 25 parts of Chinese cassia tree, 15 parts of Chinese yam and ginsenoside 15
Part.
6. the preparation method of the Chinese medicine for treating diabetes composition with lumbar vertebra disease is treated according to claim 1-5 any one of them,
It is characterized in that, the preparation method includes the following steps:
(1) medicinal material of parts by weight is spare needed for weighing;
(2) Rhizoma Chuanxiong is taken to shred, 60% ethanol wet 8~15 minutes adds in 65% ethyl alcohol into the medicinal material after wetting and impregnates 6~10
Hour, the medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~180ml/
The speed of min/kg medicinal materials carries out diacolation, collects percolate, removal solvent is up to Rhizoma Chuanxiong extract;
(3) Radix Paeoniae Alba is taken to shred, 55% ethanol wet 10~15 minutes, added in into the medicinal material after wetting 70% ethyl alcohol impregnate 10~
15 hours, the medicinal material after immersion is placed in percolate pot to 75% alcohol solvent for adding in 5~6 times of medicinal material amounts, with 160~180ml/
The speed of min/kg medicinal materials carries out diacolation, collects percolate, removal solvent is up to radix paeoniae alba extraction;
(4) Radix Ophiopogonis with 35~45 degrees Celsius of flooding twice, 1~1.5 hour every time, merge leaching liquor, filtration, filtrate concentration
To the thick paste that relative density is 1.2~1.3;
(5) 50~60% ethanol percolations of Schisandra chinensis collect percolate, recycle ethyl alcohol, are concentrated into thick paste;
(6) after Chinese cassia tree is crushed, with the extraction of 70%~85% ethanol solution twice, merge extracting solution, extracting solution is concentrated into nothing
Alcohol taste adds the water of doubling dose to dilute and stirs evenly, stands and remove sediment, obtain cinnamomum cassia extract;
(7) lycopodium calvatum, rhizoma atractylodis, Radix Glycyrrhizae, pueraria lobata, Poria cocos, rhizoma alismatis water decoct 3~4 times, 2.5~3.5 hours every time, merge and decoct
Boil liquid, filtering, filtrate are concentrated into the thick paste that relative density is 1.15~1.25, cooling, add in ethyl alcohol make alcohol content for 40%~
60%, it stands, takes supernatant, recycle ethyl alcohol, concentration and gained thick paste and extract in Chinese yam fine powder, ginsenoside, (2)-(6)
Merge, dry, adding pharmaceutic adjuvant, routinely dosage form needed for clinic is made in preparation process.
7. treatment according to claim 6 exists with the preparation method of the Chinese medicine for treating diabetes composition of lumbar vertebra disease, feature
In, the dosage form be granule, tablet, pill, capsule, injection or oral liquid, tincture, suppository, mixture, powder, lotion,
Film or dripping pill.
8. treatment according to claim 6 exists with the preparation method of the Chinese medicine for treating diabetes composition of lumbar vertebra disease, feature
In, can also be added in the dosage form ethylhydroxyethylcellulose, chitin, methylcellulose, sodium alginate, potassium alginate,
Calcium alginate, hydroxyethyl cellulose, hydroxypropyl cellulose or dextrin.
9. treatment according to claim 6 exists with the preparation method of the Chinese medicine for treating diabetes composition of lumbar vertebra disease, feature
In, the dosage form be granule, every gram of 3~6mg containing ginsenoside Re of the granule.
10. treatment according to claim 6 exists with the preparation method of the Chinese medicine for treating diabetes composition of lumbar vertebra disease, feature
In the assay method of the ginsenoside Re is:
The preparation of reference substance solution:It is appropriate that precision weighs ginsenoside Re's reference substance, and methanol is added to be respectively prepared in every 1ml and contains ginseng
The solution of saponin(e Re 0.4mg, as reference substance solution;
The preparation of test solution:This product is taken, is ground well, precision weighs 1 gram, and add methylene chloride 15ml, and water-bath flows back 0.5 hour,
Filtration, discards dichloromethane, and residue volatilizes adds the water 2ml of n-butanol saturation soak after solvent together with filter paper, precision addition water
Saturation n-butanol 40ml ultrasonic extraction 30min, precision measure supernatant, and twice times of amount of ammonification test solution shakes up, take upper solution,
Be evaporated, residue adds ethyl alcohol to dissolve, and quantitatively moves in 2ml measuring bottles, ethyl alcohol is added to be diluted to scale, shake up to get;
Chromatographic condition:It is filler with octadecylsilane chemically bonded silica;
- 0.05% phosphoric acid solution of acetonitrile that volume ratio is 50: 80 is mobile phase;Detection wavelength 203nm;Measuring method:It is accurate respectively
Reference substance solution and each 10 μ l of test solution are drawn, injects hplc determination.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810163406.XA CN108159258A (en) | 2018-02-27 | 2018-02-27 | Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810163406.XA CN108159258A (en) | 2018-02-27 | 2018-02-27 | Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108159258A true CN108159258A (en) | 2018-06-15 |
Family
ID=62511692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810163406.XA Pending CN108159258A (en) | 2018-02-27 | 2018-02-27 | Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108159258A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108567958A (en) * | 2018-07-25 | 2018-09-25 | 杭州光启医疗科技发展有限公司 | A kind of pharmaceutical composition and preparation method thereof for treating gynaecological imflammation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1399171A1 (en) * | 2001-05-03 | 2004-03-24 | Holomed Pharmaceuticals Ltd. | Medicinal herbal compounds for the prevention and treatment of diabetes |
CN1616014A (en) * | 2004-09-17 | 2005-05-18 | 鲁南制药股份有限公司 | Chinese medicine composition for treating diabetes and its preparing method |
-
2018
- 2018-02-27 CN CN201810163406.XA patent/CN108159258A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1399171A1 (en) * | 2001-05-03 | 2004-03-24 | Holomed Pharmaceuticals Ltd. | Medicinal herbal compounds for the prevention and treatment of diabetes |
CN1616014A (en) * | 2004-09-17 | 2005-05-18 | 鲁南制药股份有限公司 | Chinese medicine composition for treating diabetes and its preparing method |
Non-Patent Citations (2)
Title |
---|
刘文广等: "《临床骨科学新进展》", 28 February 2017, 上海世界图书出版公司 * |
王文友: "《王文友行医60年临床经验集》", 31 July 2017, 中国中医药出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108567958A (en) * | 2018-07-25 | 2018-09-25 | 杭州光启医疗科技发展有限公司 | A kind of pharmaceutical composition and preparation method thereof for treating gynaecological imflammation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
CN101879268B (en) | Method for preparing Chinese medicinal oral liquid for treating attention deficit hyperactivity disorder | |
CN102697781B (en) | Application of trigonelline in preparation of medicament for preventing and treating diabetes and complication thereof | |
CN108159258A (en) | Treatment is with Chinese medicine for treating diabetes composition of lumbar vertebra disease and preparation method thereof | |
CN103919939A (en) | Application of japanese banana stem and leaf extract to preparation of medicament for treating or preventing diabetes | |
CN102895459A (en) | Longevity-prolonging health-strengthening donkey-hide gelatin jelly | |
CN101455778B (en) | Traditional Chinese medicine preparation capable of reducing fever and relieving sore-throat and preparation method thereof | |
CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
CN100400081C (en) | Medicine for treating diabetes and production method thereof | |
CN104474103B (en) | A kind of natural plant hypoglycemic agent and preparation method thereof | |
CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
CN103191222B (en) | Application of hedan preparation in preparation of diabetes medicine | |
CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
CN101293059B (en) | Compound Chinese medicine for treating diabetes | |
CN103041288B (en) | A kind of Chinese medicine composition and preparation technology treating diabetic fatty liver | |
CN1943719B (en) | A Chinese traditional medicinal composition for treating diabetes and its preparation method | |
CN1167633A (en) | Process for preparation of oral liquid for strengthening waist and kidney | |
CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
CN108159233A (en) | A kind of Chinese medicine composition for treating diabetes and preparation method thereof | |
CN107669860A (en) | A kind of Chinese medicine composition and its application with blood sugar reducing function | |
CN108186821A (en) | A kind of Chinese medicine composition for treating nervous headache and its preparation method and application | |
CN116832083B (en) | Preparation process and application of traditional Chinese medicine tea beverage composition capable of preventing early glycolipid metabolic disorder | |
CN104027450B (en) | A kind of Chinese medicine composition for the treatment of diabetes | |
CN106942439A (en) | A kind of blue or green money willow Guava Leaf blood-sugar reducing tea and its production and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180615 |
|
RJ01 | Rejection of invention patent application after publication |